Stock Market News2 days Geron Stock Rallies More Than 60% in a Year: Here’s Why Zacks
FDA’s approval of GERN’s Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
XFDA’s approval of GERN’s Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
X